{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:36:52Z","timestamp":1790804212941,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL-70227"],"award-info":[{"award-number":["R01 HL-70227"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001277","name":"Oishei Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001277","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005496","name":"American Foundation for Pharmaceutical Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005496","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.xphs.2016.06.018","type":"journal-article","created":{"date-parts":[[2016,7,31]],"date-time":"2016-07-31T19:06:25Z","timestamp":1469991985000},"page":"3097-3104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Phosphatidylserine Converts Immunogenic Recombinant Human Acid Alpha-Glucosidase to a Tolerogenic Form in a Mouse Model of Pompe Disease"],"prefix":"10.1016","volume":"105","author":[{"given":"Jennifer L.","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathy V.","family":"Balu-Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.xphs.2016.06.018_bib1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","article-title":"Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy","volume":"14","author":"Chirmule","year":"2012","journal-title":"AAPS J"},{"issue":"24","key":"10.1016\/j.xphs.2016.06.018_bib2","doi-asserted-by":"crossref","first-page":"17051","DOI":"10.1074\/jbc.C112.396325","article-title":"Exposure to factor VIII protein in the presence of phosphatidylserine induces hypo-responsiveness toward factor VIII challenge in hemophilia A mice","volume":"288","author":"Gaitonde","year":"2013","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.xphs.2016.06.018_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bj0860011","article-title":"Alpha-glucosidase deficiency in generalized glycogen storage disease (Pompe's disease)","volume":"86","author":"Hers","year":"1963","journal-title":"Biochem J"},{"issue":"2","key":"10.1016\/j.xphs.2016.06.018_bib4","first-page":"132","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.xphs.2016.06.018_bib5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet Med"},{"issue":"9","key":"10.1016\/j.xphs.2016.06.018_bib6","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet Med"},{"issue":"8","key":"10.1016\/j.xphs.2016.06.018_bib7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.xphs.2016.06.018_bib8","series-title":"Myozyme [package insert]","year":"2006"},{"key":"10.1016\/j.xphs.2016.06.018_bib9","series-title":"Lumizyme [package insert]","year":"2010"},{"issue":"4","key":"10.1016\/j.xphs.2016.06.018_bib10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ymgme.2012.01.019","article-title":"Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells","volume":"105","author":"Banugaria","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.xphs.2016.06.018_bib11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet Med"},{"issue":"6","key":"10.1016\/j.xphs.2016.06.018_bib12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/eci.12.40","article-title":"Immune modulation in Pompe disease treated with enzyme replacement therapy","volume":"8","author":"Banugaria","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.xphs.2016.06.018_bib13","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/jps.21102","article-title":"Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A","volume":"97","author":"Ramani","year":"2008","journal-title":"J\u00a0Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2016.06.018_bib14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0021-9258(18)70226-3","article-title":"Phosphorus assay in column chromatography","volume":"234","author":"Bartlett","year":"1959","journal-title":"J\u00a0Biol Chem"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2016.06.018_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.xphs.2016.06.018_bib16","series-title":"GAAtm1Rabn Standard PCR. Version 3.0","year":"2009"},{"issue":"1","key":"10.1016\/j.xphs.2016.06.018_bib17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2249.2008.03602.x","article-title":"Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model","volume":"152","author":"Joseph","year":"2008","journal-title":"Clin Exp Immunol"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2016.06.018_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-1759(98)00170-7","article-title":"A\u00a0statistically defined endpoint titer determination method for immunoassays","volume":"221","author":"Frey","year":"1998","journal-title":"J\u00a0Immunol Methods"},{"issue":"1","key":"10.1016\/j.xphs.2016.06.018_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-1759(98)00204-X","article-title":"An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow","volume":"223","author":"Lutz","year":"1999","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.xphs.2016.06.018_bib20","series-title":"Drug Des Discov","first-page":"267","article-title":"In\u00a0vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting","author":"Gaitonde","year":"2011"},{"issue":"3","key":"10.1016\/j.xphs.2016.06.018_bib21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2567.2008.02996.x","article-title":"Dexamethasone\/1alpha-25-dihydroxyvitamin D3-treated dendritic cells suppress colitis in the SCID T-cell transfer model","volume":"127","author":"Pedersen","year":"2009","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.xphs.2016.06.018_bib22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1751-1097.1973.tb06422.x","article-title":"Fluorescence and the location of tryptophan residues in protein molecules","volume":"18","author":"Burstein","year":"1973","journal-title":"Photochem Photobiol"},{"issue":"4","key":"10.1016\/j.xphs.2016.06.018_bib23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1751-1097.1989.tb09183.x","article-title":"Acrylamide quenching of tryptophan photochemistry and photophysics","volume":"49","author":"Tallmadge","year":"1989","journal-title":"Photochem Photobiol"},{"issue":"30","key":"10.1016\/j.xphs.2016.06.018_bib24","doi-asserted-by":"crossref","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted disruption of the acid \u03b1-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II","volume":"273","author":"Raben","year":"1998","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"10.1016\/j.xphs.2016.06.018_bib25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2012.03.009","article-title":"Mapping the T helper cell response to acid \u03b1-glucosidase in Pompe mice","volume":"106","author":"Nayak","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.xphs.2016.06.018_bib26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.0105-2896.2010.00903.x","article-title":"TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity","volume":"235","author":"Freeman","year":"2010","journal-title":"Immunol Rev"},{"issue":"8","key":"10.1016\/j.xphs.2016.06.018_bib27","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1002\/jps.24513","article-title":"Exposure of FVIII in the presence of phosphatidyl serine reduces generation of memory B-Cells and induces regulatory T-cell-mediated hyporesponsiveness in hemophilia a mice","volume":"104","author":"Ramakrishnan","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2016.06.018_bib28","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0021-9258(19)40122-1","article-title":"Binding of human factor VIII to phospholipid vesicles","volume":"265","author":"Gilbert","year":"1990","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.xphs.2016.06.018_bib29","series-title":"Bioinformatics--Trends and Methodologies","article-title":"Structural bioinformatics analysis of acid alpha-glucosidase mutants with pharmacological chaperones","author":"Ho","year":"2011"},{"issue":"18","key":"10.1016\/j.xphs.2016.06.018_bib30","doi-asserted-by":"crossref","first-page":"17593","DOI":"10.1074\/jbc.M500163200","article-title":"Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-l-serine complex","volume":"280","author":"Purohit","year":"2005","journal-title":"J\u00a0Biol Chem"},{"issue":"6","key":"10.1016\/j.xphs.2016.06.018_bib31","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/cdd.2016.11","article-title":"Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer","volume":"23","author":"Birge","year":"2016","journal-title":"Cell Death Differ"},{"issue":"8","key":"10.1016\/j.xphs.2016.06.018_bib32","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.20021215","article-title":"Immune tolerance after delivery of dying cells to dendritic cells in","volume":"196","author":"Liu","year":"2002","journal-title":"Situ J Exp Med"},{"issue":"4","key":"10.1016\/j.xphs.2016.06.018_bib33","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.20040342","article-title":"Masking of phosphatidylserine inhibits apoptotic cell engulfment and induces autoantibody production in mice","volume":"200","author":"Asano","year":"2004","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"10.1016\/j.xphs.2016.06.018_bib34","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.4049\/jimmunol.174.3.1393","article-title":"Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in\u00a0vivo","volume":"174","author":"Hoffmann","year":"2005","journal-title":"J\u00a0Immunol"},{"issue":"241","key":"10.1016\/j.xphs.2016.06.018_bib35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1126\/scitranslmed.3008895","article-title":"In\u00a0vivo\u2013generated antigen-specific regulatory T cells treat autoimmunity without compromising antibacterial immune response","volume":"6","author":"Kasagi","year":"2014","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.xphs.2016.06.018_bib36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.clim.2010.10.006","article-title":"Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function","volume":"138","author":"Gaitonde","year":"2011","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.xphs.2016.06.018_bib37","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1208\/s12248-013-9510-6","article-title":"Immunogenicity of subcutaneously administered therapeutic proteins\u2014a mechanistic perspective","volume":"15","author":"Fathallah","year":"2013","journal-title":"AAPS J"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916415169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916415169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T13:20:20Z","timestamp":1656940820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916415169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0022354916415169"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2016.06.018","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphatidylserine Converts Immunogenic Recombinant Human Acid Alpha-Glucosidase to a Tolerogenic Form in a Mouse Model of Pompe Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2016.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}